A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to a phase 2 clinical trial. The study results compared an investigational drug called basal insulin Fc (BIF) with insulin degludec, a commercially available long-lasting daily insulin, in patients with type 2 diabetes.
source https://www.sciencedaily.com/releases/2021/03/210321215440.htm
Monday, 22 March 2021
Related Posts
Face mask insert could help diagnose conditionsResearchers have demonstrated that a fiber inserted into an ordinary N… Read More
Adaptation in single neurons provides memory for language processingTo understand language, we have to remember the words that were uttere… Read More
Flipping a metabolic switch to slow tumor growthThe enzyme serine palmitoyl-transferase can be used as a metabolically… Read More
Engaging undergrads remotely with an escape room gameResearchers describe an alternative way to engage students: a virtual … Read More
Soldiers could teach future robots how to outperform humansResearchers have designed an algorithm that allows an autonomous groun… Read More
Researchers identify a protein that may help SARS-CoV-2 spread rapidly through cellsNew research identifies a protein encoded by SARS-CoV-2, the virus tha… Read More
0 comments: